Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ID93 Vaccine with AP10-602 or GLA-SE in Healthy Adults
NCT02508376Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2015
- Primary completion
- Aug 2017
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ID93 in Tuberculosis (TB), sponsored by National Institute of Allergy and Infectious Diseases. Started Oct 2015; status: completed.
02
Drugs
ID93
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02508376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508376.